-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate cost of goods produced and sold and services rendered during the reporting period.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Cost of Revenue history and growth rate from Q4 2021 to Q2 2025.
- InMed Pharmaceuticals Inc. Cost of Revenue for the quarter ending June 30, 2025 was $728K, a 10.9% decline year-over-year.
- InMed Pharmaceuticals Inc. Cost of Revenue for the twelve months ending June 30, 2025 was $3.24M, a 7.46% decline year-over-year.
- InMed Pharmaceuticals Inc. annual Cost of Revenue for 2025 was $3.24M, a 7.46% decline from 2024.
- InMed Pharmaceuticals Inc. annual Cost of Revenue for 2024 was $3.5M, a 28% increase from 2023.
- InMed Pharmaceuticals Inc. annual Cost of Revenue for 2023 was $2.73M, a 401% increase from 2022.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)